




RealRate

PHARMACEUTICAL 2022

BELLICUM PHARMACEUTICALS INC
Rank 202 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

BELLICUM PHARMACEUTICALS INC Rank 202 of 475



The relative strengths and weaknesses of BELLICUM PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BELLICUM PHARMACEUTICALS INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 221% points. The greatest weakness of BELLICUM PHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 137% points.

The company's Economic Capital Ratio, given in the ranking table, is -64%, being 212% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	49,131
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,712
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	1.0
Other Expenses	0
Other Liabilities	0
Other Net Income	14,683
Property and Equipment	12
Research and Development	23,578
Revenues	0
Selling, General and Administrative Expense	7,010

Output Variable	Value in 1000 USD
Assets	49,143
Liabilities	6,712
Expenses	30,588
Stockholders Equity	42,431
Net Income	-15,905
Comprehensive Net Income	-15,904
Economic Capital Ratio	-64%

